Nivolumab plus ipilimumab in malignant pleural mesothelioma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2102482
Abstract: ABSTRACT Introduction Unresectable pleural mesothelioma is a poor prognosis disease. Improvement in overall survival (OS) has been shown with PEMETREXED combined with CISPLATIN. BEVACIZUMAB combined with chemotherapy is associated with an improvement in OS, compared… read more here.
Keywords: malignant pleural; pleural mesothelioma; mesothelioma; ipilimumab malignant ... See more keywords